Research General gynecology| Volume 204, ISSUE 3, P211.e1-211.e6, March 2011

Download started.


Tinidazole vs metronidazole for the treatment of bacterial vaginosis

Published:December 20, 2010DOI:


      The purpose of this study was to compare the efficacy of 2 different doses of tinidazole with metronidazole for the treatment of bacterial vaginosis and to compare the side effects of the drugs.

      Study Design

      Women were assigned randomly to receive metronidazole 500 mg twice daily, tinidazole 500 mg twice daily, or tinidazole 1 g twice, all for 7 days. Follow-up visits were conducted at days 14 and 28.


      Five hundred ninety-three women were enrolled. There were no significant differences between the treatment arms. Overall cure rates were 76.8% at 14 days and 64.5% at 1 month. Women who admitted to engaging in sexual intercourse during the study were significantly more likely to have bacterial vaginosis at the follow-up visit. There were no significant differences in adverse events across treatment arms.


      There were no differences in cure rates between metronidazole and either of the tinidazole dosing regimens that were studied. In addition, there were no important differences in the side-effect profiles of metronidazole and tinidazole.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fleury F.J.
        Adult vaginitis.
        Clin Obstet Gynecol. 1981; 24: 407-438
        • Eschenbach D.A.
        Bacterial vaginosis and anaerobes in obstetric-gynecologic infection.
        Clin Infec Dis. 1993; 16: S282-S287
        • Hillier S.
        The vaginal microbial ecosystem and resistance to HIV.
        AIDS. 1998; 14: 17-21
        • Martin H.
        • Richardson B.A.
        • Nyange P.M.
        • et al.
        Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition.
        J Infect Dis. 1999; 180: 1863-1868
        • Joesoef M.R.
        • Schmid G.P.
        • Hillier S.L.
        Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.
        Clin Infect Dis. 1999; 28: S57-S65
        • Livengood C.R.
        • Ferris D.G.
        • Wiesenfeld H.C.
        • et al.
        Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial.
        Obstet Gynecol. 2007; 110: 302-309
        • Amsel R.
        • Totten P.A.
        • Spiegel C.A.
        • Chen K.C.S.
        • Eschenbach D.
        • Holmes K.K.
        Non-specific vaginitis: diagnostic and microbial and epidemiological associations.
        Am J Med. 1983; 74: 14-22
        • Eschenbach D.A.
        • Hillier S.
        • Critchlow C.
        • Stevens C.
        • DeRouen T.
        • Holmes K.K.
        Diagnosis and clinical manifestations of bacterial vaginosis.
        Am J Obstet Gynecol. 1988; 158: 819-828
        • Nugent R.P.
        • Krohn M.A.
        • Hillier S.L.
        Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation.
        J Clin Microbiol. 1991; 29: 297-301
        • Draper D.
        • Parker R.
        • Patterson E.
        • et al.
        Detection of Trichomonas vaginalis in pregnant women with the InPouch TV system.
        J Clin Microbiol. 1993; 31: 1016-1018
        • Rein M.F.
        • Holmes K.K.
        ”Non-specific vaginitis,” vulvovaginal candidiasis, and trichomoniasis clinical features, diagnosis and management.
        Curr Clin Top Infec Dis. 1983; 4: 281-315
        • Josey W.
        • Schwebke J.
        The polymicrobial hypothesis of bacterial vaginosis causation: a reassessment.
        Int J STD AIDS. 2008; 19: 152-154
        • Ekgren J.
        • Norling B.
        • Degre M.
        • Midret T.
        Comparison of tinidazole given as a single dose and on 2 consecutive days for the treatment of nonspecific bacterial vaginosis.
        Gynecol Obstet Invest. 1988; 26: 313-317
        • Buranawarodomkul P.
        • Chandeying V.
        • Sutthijumroon S.
        Seven day metronidazole versus single dose tinidazole as therapy for nonspecific vaginitis.
        J Med Assoc Thai. 1990; 73: 283-287
        • Sanz Sanz F.
        • Hernanz A.
        • Sancher E.
        Comparative trial of metronidazole versus tinidazole in the treatment of nonspecific vaginitis.
        Rev Esp Obstet Ginecol. 1985; 44: 717-720
        • Milani M.
        • Barcelona E.
        • Agnello A.
        Efficacy of the combination of 2 g oral tinidazole and acidic buffering vaginal gel in comparison with vaginal clindamycin alone in bacterial vaginosis: a randomized, investigator-blinded, controlled trial.
        Eur J Obstet Gynecol Reprod Biol. 2003; 19: 67-71